SK Hynix Q2 profit expected to reach 60-70 trillion won, driven to a new high by AI memory demand
BlockBeats News, June 19 — Market analysts generally expect that the company's operating profit in the second quarter of 2026 will be in the range of 60 trillion to 70 trillion KRW, far higher than the record high of 37.6 trillion KRW set in the first quarter.
The Q1 financial report released in April shows SK hynix's revenue reached 52.58 trillion KRW, with operating profit at 37.61 trillion KRW and an operating margin as high as 72%, both setting new quarterly records. The core drivers of this surge are the strong demand and price increase for high bandwidth memory (HBM) and high-end DRAM. Management pointed out that the structural memory shortage driven by AI infrastructure will last at least three years.
Entering the second quarter, expectations of rising memory prices have further boosted profit prospects. Analysts expect DRAM and NAND contract prices to rise another 50% to over 70% quarter-on-quarter. With a product structure focused on high-margin items, even a slight price increase exerts a significant leverage effect on SK hynix. The current market consensus puts the Q2 median operating profit at around 62 trillion to 64 trillion KRW, with some brokerage firms like Kiwoom Securities raising their forecast to 70 trillion KRW, while earlier consensus was only around 40 trillion KRW. This optimism is already reflected in the share price.
Since the beginning of this year, SK hynix’s cumulative increase has exceeded 300%, and at the end of May its market capitalization briefly surpassed 1 trillion USD, making it the second Asian chip company to join the "trillion-dollar club" after Samsung Electronics. By comparison, the market expects Samsung Electronics' memory business Q2 profit to also be raised to the 70 trillion KRW level, with the combined industry profits from these two Korean giants rapidly expanding.
Although geopolitical and AI capital expenditure timing uncertainties remain, HBM technological barriers and long-term supply-demand imbalances give SK hynix a clear advantage in the current memory upcycle. The company’s Q2 financial report is expected to be released in late July, when the market will test the extent to which these aggressive forecasts are realized. For investors focused on the AI theme, SK hynix remains one of the most direct beneficiaries at present.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BAE Systems wins Lockheed Martin contract to supply electronic warfare systems for F-35 jets
BAE Systems won a Lockheed Martin contract to supply electronic warfare systems for F-35 Lightning II fighter jets. Order covers production deliveries for F-35 Lots 20-22. Deal also includes retrofit systems to modernize older aircraft in the global F-35 fleet. BAE Systems has delivered more than 1,500 F-35 electronic warfare systems to date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BAE Systems plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061000PR_NEWS_USPR_____NE64821) on October 06, 2026, and is solely responsible for the information contained therein.
Japanese Yen: Range trade holds against US Dollar as Fed path questioned – Rabobank
BUZZ-GEO Group shares rise after completing $650 million debt refinancing
On October 6, shares of prison operator GEO Group (GEO.N) rose 2.6% in premarket trading to $33.19. The company conducted a debt refinancing, redeeming $650 million in senior secured notes due in 2029. Its $550 million revolving credit facility maturity was extended to July 2031. Earlier this week, the company agreed to sell its ICE processing center complex in Adelanto, California for $950 million. The company also recently increased its share repurchase authorization to $1.25 billion. As of the close of the previous trading day, the company's share price had more than doubled this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them for the convenience of readers only. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Updated: 2-ArriVent’s oral lung cancer therapy fails in late-stage clinical trial, shares plunge
In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)
Crypto prices
More
